S&P 500

5.346,99

-0,11%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Social Capital Suvretta Holdings Corporation III (DNAC)
Social Capital Suvretta Holdings Corporation III (DNAC) Notícias

DNAC

Social Capital Suvretta ... (DNAC)

Social Capital Suvretta Holdings Corporation III

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:DNAC

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
16/06/2023	17:07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
26/05/2023	09:01	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
26/05/2023	08:33	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
11/05/2023	17:11	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
21/04/2023	07:04	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
17/04/2023	18:02	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
04/04/2023	17:47	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
29/03/2023	07:06	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
28/03/2023	17:47	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
14/02/2023	14:24	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
06/01/2023	18:59	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
26/08/2022	17:07	Edgar (US Regulatory)	Securities Registration Statement (s-1/a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
12/08/2022	08:16	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
09/08/2022	07:10	Edgar (US Regulatory)	Securities Registration Statement (s-1)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
22/07/2022	17:40	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
22/07/2022	07:01	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
20/07/2022	17:32	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
12/07/2022	09:00	GlobeNewswire Inc.	Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
08/07/2022	20:36	Business Wire	Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
06/07/2022	09:46	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
23/06/2022	09:00	GlobeNewswire Inc.	ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
15/06/2022	09:00	GlobeNewswire Inc.	ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing Costs	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
10/06/2022	17:55	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
07/06/2022	09:00	GlobeNewswire Inc.	Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
20/05/2022	10:00	GlobeNewswire Inc.	ProKidney to present at upcoming investor conferences	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
06/05/2022	17:48	Edgar (US Regulatory)	Proxy Soliciting Materials (revised) (prer14a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
03/05/2022	09:00	GlobeNewswire Inc.	ProKidney highlights key registrational program elements supporting advancement of REACT®	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
18/04/2022	10:30	GlobeNewswire Inc.	ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
12/04/2022	09:00	GlobeNewswire Inc.	ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III
14/02/2022	19:14	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (preliminary) (prem14a)	NASDAQ:DNAC	Social Capital Suvretta Holdings Corporation III